3 Horrendous Health-Care Stocks This Week

We're back yet again, with our review of three of the most horrendous health-care stocks of the past week. Let's get right to it an review some of the big losers over the past few days.

Given up?
Shares of Israeli medical device maker Given Imaging (UNKNOWN: GIVN.DL  ) dropped nearly 12% this week. The steep fall came after a double-whammy of bad news.

Given announced on Tuesday that it's abandoning plans to sell to or merge with another company. The company said in October that it had attracted interest from several parties and was looking seriously at the potential for a deal. That deal ultimately didn't materialize.

The other bad news was that the largest holder of Given Imaging stock, Discount Investment Corporation, is looking to sell all of its 45.5% stake. DIC is a major investment firm in Israel and owns large positions in several Israeli firms, including the nation's largest cellular operator and largest grocery retail chain.

A noteworthy decline
Theravance
(NASDAQ: THRX  ) shares sank more than 10% this week. The biopharmaceutical company announced on Wednesday that it plans to offer $250 million in convertible subordinated notes due in 2023.

One major reason Theravance cited for taking on more debt was to make potential milestone payments to its collaboration partner, GlaxoSmithKline (NYSE: GSK  ) . Theravance and Glaxo recently submitted for a Marketing Authorization Approval in Europe for COPD drug Anoro and have also submitted to the FDA for approval for the drug in the United States.

Theravance also will probably use a portion of the new debt to pay off some old debt. The company has $172.5 million in convertible subordinated notes that mature at the beginning of 2015.  

The dilution solution
Aveo Pharmaceuticals
(NASDAQ: AVEO  ) shares tumbled 10% this week after announcing on Thursday that it intends to move forward with a $50 million secondary public offering.

The main factor for needing to generate more cash stems from the expected commercial launch of tivozanib later this year. The kidney cancer drug, developed by Aveo and partner Astellas Pharma, has an FDA decision date of July 28. 

Aveo's secondary offering of nearly 6.7 million shares represents about 15% of the company's total outstanding shares. The market seems to be pricing in a reasonable potential for FDA approval of tivozanib, since Aveo shares didn't fall as much as they could have with that amount of dilution.

Horrendously horrendous
What's the worst of the worst this week aside from the percentage drop for each stock? I'd have to say that Given Imaging gets the nod. Theravance and Aveo fell for temporary reasons that directly relate to long-term positives. Given, on the other hand, had its biggest owner say shalom (for goodbye, not hello) and saw prospects for a merger or buyout fall through. That qualifies for a horrendous week and potentially horrendous days ahead for the stock.

While you can certainly make humongous gains in biotech and pharmaceuticals, you can also take horrendous losses. The best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2205256, ~/Articles/ArticleHandler.aspx, 9/22/2014 6:45:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement